“Bringing Altitude into our Series B financing was one of my best decisions as CEO. Dave Maki brought amazing expertise and support, especially in the area of Intellectual Property. He contributed in setting strategic direction for our IP estate, helped us solve difficult problems with the Patent Office, and assisted in diligence with potential partners. A true value-add investor.”
- Keith Leonard, CEO, Kythera Biopharma
Dave Maki | Managing Partner
Dave has been associated with life science organizations for over 30 years and co-founded Altitude Life Science Ventures in 2005. Prior to founding Altitude, he served as a Partner with Perennial Ventures and as a Vice President with Tredegar Investments. From 1987 to 1999, he served as a Partner at the intellectual property firm of Seed and Berry (now Seed IP Law), where he focused on strategic planning for healthcare companies, particularly in relation to R&D planning, competitive analysis, and corporate collaborations and licensing transactions. During the latter portion of his 17 year tenure at the firm, Dave served in the roles of Managing Partner and Financial Partner. Under his leadership as Senior Partner in the Biotechnology Group, the firm built a client base of over 60 healthcare companies. Dave currently serves as a Director on the Board of Effector Therapeutics, and previously served on the Board of Omniome and was Chairman of the Board of the Infectious Disease Research Institute.
Kristen Wong | Associate
Kristen joined Altitude Life Science Ventures in 2015. Prior to Altitude, she worked at Bayer HealthCare where she was responsible for high level project management activities for the commercialization of two pipeline drugs with expenditures totaling more than $150M. These activities included a high priority project to collect and analyze issues pertaining to the commercial manufacturing process and to ensure follow-through and close-out of critical activities. Disciplined adherence to these tight timelines, communication with cross-functional teams, and resolution of complex issues were of upmost importance to ensure that these drug products remained within company timelines for FDA submission and licensure. Kristen has also held roles as a Conformance Investigator and Process Development Scientist. She holds a MBA from University of North Carolina Kenan-Flagler Business School and undergraduate and Master’s degrees in Biology from Stanford University.